Cepham, a Somerset-based nutraceutical research and development firm, is taking strategic steps to bridge the gender gap in health research and innovation, with a focus on women’s health.
Cepham’s plan includes increased funding for underrepresented areas, inclusive research designs, and enhanced communication to raise awareness and support for women’s health initiatives including Women in Nutraceuticals.
“It typically takes 15-20 years for research discoveries to be adopted into clinical practice. This delay is a significant barrier to implementing new findings in women’s health,” Anand Swaroop, founder and president of Cepham, and director at large for WIN, said. “By closing these research gender gaps, we can ensure that women’s health issues receive the attention and resources needed for better health outcomes.”
Swaroop went on to say that immediate policy interventions, driven by insights from successful case studies and a commitment to inclusive research, are essential to fostering a future where women’s health is prioritized and adequately funded.
An investor in women’s health research since 2013, one of Cepham’s flagship products, Furocyst, is a proprietary fenugreek seed extract developed to support insulin sensitivity and reduce ovarian cysts. It has been clinically evaluated on 520 patients and shown to improve glucose metabolism and hormonal balance, making it a promising solution for managing polycystic ovary syndrome.
